Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Heart symbols : LLY save search
Heart Failure Treatment Drug Market to Accelerate Immensely by 2032, Predicts DelveInsight
Published: 2024-01-15 (Crawled : 22:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.15%
H: 0.59%
C: -1.45%
drug treatment heart market
Redwire Announces First Spaceflight Mission for New Cutting-Edge Pharmaceutical Drug Development Lab, Partnering with Eli Lilly and Company to Expand Space Research to Study Heart Disease and Diabetes
Published: 2023-10-30 (Crawled : 13:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: 0.0%
drug disease company space research heart diabetes study
Innovent Releases Results of a Phase 3 Clinical Study of Tafolecimab（IBI306）in Chinese Patients with non- Familial Hypercholesterolemia at the American Heart Association (AHA) Scirntific Sessions 2022
Published: 2022-11-07 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -2.01%
H: 0.88%
C: 0.88%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.17%
H: 2.51%
C: 1.97%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.46%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.25%
H: 0.46%
C: -2.05%
ibi306 sessions chinese heart results study hypercholesterolemia
Ancora Heart Appoints Mark Miles as Chief Commercial Officer
Published: 2022-06-23 (Crawled : 13:20) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 4.14%
H: 0.0%
C: 0.0%
commercial heart miles
Jardiance® decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world evidence study
Published: 2022-06-05 (Crawled : 00:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 3.83%
H: 0.0%
C: 0.0%
jardiance risk heart diabetes
Heart Failure Treatment Offers Hope to Diabetics
Published: 2022-05-11 (Crawled : 12:00) - prnewswire.com
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: -2.55%
H: 2.32%
C: -0.85%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.33%
H: 0.0%
C: 0.0%
treatment heart
JARDIANCE (empagliflozin) becomes the first and only approved treatment in Canada for adults with chronic heart failure regardless of ejection fraction
Published: 2022-04-12 (Crawled : 15:20) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.77%
H: 0.99%
C: 0.49%
treatment canada heart jardiance
Jardiance® provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE phase III trial
Published: 2022-03-01 (Crawled : 16:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 1.26%
H: 0.0%
C: 0.0%
jardiance heart trial
AnHeart Therapeutics and Innovent Biologics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer
Published: 2022-03-01 (Crawled : 15:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 1.26%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.44%
H: 2.1%
C: 0.88%
heart therapeutics cel lung cancer positive cancer designation
Innovent Biologics and AnHeart Therapeutics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer
Published: 2022-03-01 (Crawled : 02:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 1.26%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.44%
H: 2.1%
C: 0.88%
heart therapeutics cel lung cancer positive cancer designation
US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
Published: 2022-02-24 (Crawled : 00:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -1.4%
H: 0.0%
C: 0.0%
jardiance fda heart
US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction
Published: 2021-11-11 (Crawled : 19:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
new drug fda heart application drug fda acceptance
Jardiance® shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status
Published: 2021-11-05 (Crawled : 19:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
| Email alert
Add to watchlist
disease heart renal cardio kidney
AnHeart and Innovent Announce Interim Data from Phase Ⅱ Trial (TRUST) of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting
Published: 2021-09-27 (Crawled : 13:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -1.21%
H: 0.47%
C: -1.55%
heart positive trial
Innovent and AnHeart Announce Interim Data from Phase 2 Trial of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting
Published: 2021-09-27 (Crawled : 00:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -1.21%
H: 0.47%
C: -1.55%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.89%
H: 0.54%
C: 0.51%
phase 2 heart positive trial
FDA grants Jardiance® Breakthrough Therapy designation for heart failure with preserved ejection fraction
Published: 2021-09-09 (Crawled : 14:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.61%
H: 0.29%
C: -5.25%
fda heart therapy breakthrough therapy granted grant designation
Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
Published: 2021-08-27 (Crawled : 16:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
heart therapy trial
US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction
Published: 2021-08-18 (Crawled : 18:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.26%
H: 1.01%
C: -1.28%
fda heart fda approval
Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction
Published: 2021-07-06 (Crawled : 11:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.69%
H: 0.83%
C: 0.77%
heart results trial
AnHeart and Innovent Releases Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting
Published: 2021-06-07 (Crawled : 07:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.01%
H: 15.52%
C: 10.16%
heart positive results trial
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.